These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38377374)

  • 1. FDG PET/CT in a Case of Isolated Gastric Metastasis From Pancreatic Ductal Adenocarcinoma.
    Ji X; Dong A; Wang Y
    Clin Nucl Med; 2024 Apr; 49(4):377-378. PubMed ID: 38377374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FDG PET/CT in Pancreatic Ductal Adenocarcinoma Arising From a Heterotopic Pancreas of the Pylorus.
    Ji X; Dong A; Wang Y
    Clin Nucl Med; 2024 Jan; 49(1):e42-e44. PubMed ID: 37976432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isolated Pancreatic Metastasis From Squamous Cell Lung Cancer Mimicking Primary Pancreatic Ductal Adenocarcinoma on FDG PET/CT.
    Zhou W; Dong H; Dong A
    Clin Nucl Med; 2020 May; 45(5):420-422. PubMed ID: 32149802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of F-18-FDG PET/CT findings between pancreatic solid pseudopapillary tumor and pancreatic ductal adenocarcinoma.
    Kim YI; Kim SK; Paeng JC; Lee HY
    Eur J Radiol; 2014 Jan; 83(1):231-5. PubMed ID: 24290142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 18F-FDG PET/CT in pancreatic adenocarcinoma: A role at initial imaging staging?
    Wartski M; Sauvanet A
    Diagn Interv Imaging; 2019 Dec; 100(12):735-741. PubMed ID: 31402332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparing the clinical value of baseline [
    Ding J; Qiu J; Hao Z; Huang H; Liu Q; Liu W; Ren C; Hacker M; Zhang T; Wu W; Li X; Huo L
    Eur J Nucl Med Mol Imaging; 2023 Nov; 50(13):4036-4050. PubMed ID: 37493664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer.
    Bang S; Chung HW; Park SW; Chung JB; Yun M; Lee JD; Song SY
    J Clin Gastroenterol; 2006; 40(10):923-9. PubMed ID: 17063113
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Li X; Lu N; Lin L; Chen Y; Yang S; Wang H; Liu X; Wu C; Xue X; Su X; Bai X; Liang T
    J Nucl Med; 2024 Feb; 65(2):206-212. PubMed ID: 38176719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Role of 18F-FDG PET/CT and PET/MRI in Pancreatic Ductal Adenocarcinoma.
    Yeh R; Dercle L; Garg I; Wang ZJ; Hough DM; Goenka AH
    Abdom Radiol (NY); 2018 Feb; 43(2):415-434. PubMed ID: 29143875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 18-Fluorodeoxyglucose Positron Emission Tomography Predicts Recurrence in Resected Pancreatic Ductal Adenocarcinoma.
    Ariake K; Motoi F; Shimomura H; Mizuma M; Maeda S; Terao C; Tatewaki Y; Ohtsuka H; Fukase K; Masuda K; Hayashi H; Takadate T; Naitoh T; Taki Y; Unno M
    J Gastrointest Surg; 2018 Feb; 22(2):279-287. PubMed ID: 29119533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility of contrast-enhanced FDG-PET/CT in the clinical management of pancreatic cancer: impact on diagnosis, staging, evaluation of treatment response, and detection of recurrence.
    Asagi A; Ohta K; Nasu J; Tanada M; Nadano S; Nishimura R; Teramoto N; Yamamoto K; Inoue T; Iguchi H
    Pancreas; 2013 Jan; 42(1):11-9. PubMed ID: 22699206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pancreatic Cancer Complicated by Pancreatitis Demonstrated on FDG PET/CT.
    Hennessy G; Vamadevan S; Loh H; Bui C; Le K; Mansberg R
    Clin Nucl Med; 2017 Mar; 42(3):239-240. PubMed ID: 28098664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective comparison of (4S)-4-(3-
    Cheng MF; Huang YY; Ho BY; Kuo TC; Hsin LW; Shiue CY; Kuo HC; Jeng YM; Yen RF; Tien YW
    Eur J Nucl Med Mol Imaging; 2019 Apr; 46(4):810-820. PubMed ID: 30635754
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Palmieri LJ; Coriat R
    Diagn Interv Imaging; 2019 Dec; 100(12):731-733. PubMed ID: 31780041
    [No Abstract]   [Full Text] [Related]  

  • 15. Evaluation of pancreatic carcinoma with FDG PET.
    Jadvar H; Fischman AJ
    Abdom Imaging; 2001; 26(3):254-9. PubMed ID: 11429948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of 18F-FDG PET/CT combined with carbohydrate antigen 19-9 for differentiating pancreatic carcinoma from chronic mass-forming pancreatitis in Chinese elderly.
    Gu X; Liu R
    Clin Interv Aging; 2016; 11():1365-1370. PubMed ID: 27729779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of response using FDG-PET/CT and diffusion weighted MRI after radiochemotherapy of pancreatic cancer: a non-randomized, monocentric phase II clinical trial-PaCa-DD-041 (Eudra-CT 2009-011968-11).
    Zimmermann C; Distler M; Jentsch C; Blum S; Folprecht G; Zöphel K; Polster H; Troost EGC; Abolmaali N; Weitz J; Baumann M; Saeger HD; Grützmann R
    Strahlenther Onkol; 2021 Jan; 197(1):19-26. PubMed ID: 32638040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical application of Al
    Lyu Z; Han W; Zhang Q; Zhao H; Liu S; Wang Y; He J; Zhao C; Tian L; Fu P
    Cancer Imaging; 2023 Sep; 23(1):86. PubMed ID: 37700343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical impact of fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography in patients with resectable pancreatic cancer: diagnosing lymph node metastasis and predicting survival.
    Kim HR; Seo M; Nah YW; Park HW; Park SH
    Nucl Med Commun; 2018 Jul; 39(7):691-698. PubMed ID: 29893751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. F-18-fluorodeoxyglucose positron emission tomography in differentiating malignant from benign pancreatic cysts: a prospective study.
    Sperti C; Pasquali C; Decet G; Chierichetti F; Liessi G; Pedrazzoli S
    J Gastrointest Surg; 2005 Jan; 9(1):22-8; discussion 28-9. PubMed ID: 15623441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.